CLAIMS

- 1. A method of treating FSD which method comprises administering to a patient in need of such treatment an effective amount of a compound that is an α_{1A} and/or an α_{1L} adrenergic receptor antagonist.
- 2. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_i in a binding assay of less than 100nM, or a pA_2 greater than 7 in a functional assay.

10

- 3. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_i in a binding assay of less than 10nM, or a pA_2 greater than 8 in a functional assay.
- 4. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_1 in a binding assay of less than 1nM, or a pA_2 greater than 9 in a functional assay.
- 5. A method of claim 1, wherein the compound is a selective α_{1L} and/or a selective α_{1A} adrenergic receptor antagonist.
 - 6. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1B} receptor.
- 7. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1D} receptor.
 - 8. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1D} and α_{1B} receptors.

30


- 9. A method of claim 1, wherein FSD is FSAD and/or FOD.
- 10. A method of claim 1, wherein the compound is a compound of formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ represents C₁₋₄ alkyl;

R² represents C₃₋₆ cycloalkyl;

5 R³ represents a bicyclic group of the formula



wherein X and Y are selected from C and N, provided that at least one is C;

Ring A together with X and Y represents a 5- or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring;

Z is selected from H, and LR4;

L represents a direct link, C₁₋₄ alkylene or C₁₋₄ alkoxyalkylene;

R⁴ represents H, NR⁵R⁶, C₃₋₆ cycloalkyl, OR⁷ or Het¹;

 R^5 and R^6 are independently selected from H, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with OR^8 ;

 R^7 is selected from H, C_{1-4} alkyl, C_{1-4} alkoxyalkyl, C_{3-6} cycloalkyl, Het 2 and C_{1-4} alkyl-Het 3 ;

R⁸ is H or C₁₋₄ alkyl;

Het¹, Het² and Het³ independently represent a 4 to 7 membered saturated 20 heterocyclic group which may be mono- or bi-cyclic and which contains one or more heteroatoms selected from N, O or S, optionally substituted with OR⁹ and/or C₁₋₄ alkyl optionally substituted by OR⁹;

R⁹ is H or C₁₋₄ alkyl.

25 11. A method of claim 10, wherein the compound is selected from:

5-cyclopropyl-7-methoxy-2-(2-([dimethylamino]methyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-(1-pyrrolidinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-(4-morpholinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5

5-cyclopropyl-7-methoxy-2-(5-([dimethylamino]methyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(1-pyrrolidinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(1-piperidin ylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(4-morpholinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]- 3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or pharmaceutically acceptable salts or solvates thereof.

- 15 12. A method of claim 5, wherein the compound is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt or solvent thereof.
- 13. A method of claim 1, wherein the compound is selected from tamsulosin, doxazosin, terazosin, alfuzosin, or silodosin.
 - 14. An intravaginal formulation comprising a compound as defined in claim 1.
 - 15. A formulation as claimed in claim 14, which is a cream or a gel.

25

- 16. A method of enhancing sexual function in a female which method comprises administering to a healthy female an α_{1A} and/or an α_{1L} adrenergic receptor antagonist.
- 17. A method of screening for compounds useful for treating FSD, which method
 30 comprises screening compounds for antagonist activity against α_{1A} and/or α_{1L} adrenergic receptor, and selecting compounds with an K_i of less than 100nM, or a pA₂ greater than
 7.
- 18. A method of treating or preventing FSD which method comprises administration of a combination comprising one or more α_{1A} and/or an α_{1L} adrenergic receptor antagonists, and one or more of the following auxiliary agents:

- (a) A PDE5 inhibitor;
- (b) A neutral endopeptidase (NEP) inhibitor;
- (c) A Dopamine D3 receptor agonist;
- (d) A 5HT1A receptor agonist or a 5HT2C receptor agonist;
- 5 (e) Agents used for hormone replacement therapy (HRT); and
 - (f) Agents used in combination for HRT and additional androgen therapy.